Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06389526 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | PHASE1 | NOT YET_RECRUITING | 48 | — | — | Feb 15, 2025 | May 30, 2028 | Sep 19, 2024 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A: Single Agent CHS-1000 | EXPERIMENTAL | - |
| Part B: Combination Agents CHS-1000 + Toripalimab | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CHS-1000 | BIOLOGICAL | Specified dose on specified days |
| Toripalimab | BIOLOGICAL | Specified dose on specified days |
Key Inclusion Criteria: * Histopathologically or cytologically confirmed diagnosis of advanced or metastatic unresectable solid tumors (excluding glioblastoma multiforme (GBM)) by tissue biopsy or archival tumor specimen. Unresectable tumors are defined as tumors with lesions in which clear surgica...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |